Arif M Cosar1, Christine M Durand, Andrew M Cameron, Ahmet Gurakar. 1. aJohns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology - Transplant Hepatology bJohns Hopkins University School of Medicine, Division of Infectious Diseases cJohns Hopkins University School of Medicine, Liver Transplant Surgery, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: The treatment of hepatitis C virus infection (HCV) in liver transplant recipients was very limited until direct-acting antivirals became widely available. We review the current approach to HCV treatment following liver transplantation and future research opportunities. RECENT FINDINGS: Current treatment of HCV infection with all oral new direct-acting antivirals in the postliver transplant setting is easier, shorter, tolerable, and more effective with high-sustained virological response rates. However, some challenges remain, including the optimal timing of therapy, drug-drug interactions, renal insufficiency, and HIV coinfection. SUMMARY: Patients with recurrent HCV following liver transplant will significantly benefit from all oral new direct acting antivirals. Ongoing studies will determine the optimal timing and combination in this unique population.
PURPOSE OF REVIEW: The treatment of hepatitis C virus infection (HCV) in liver transplant recipients was very limited until direct-acting antivirals became widely available. We review the current approach to HCV treatment following liver transplantation and future research opportunities. RECENT FINDINGS: Current treatment of HCV infection with all oral new direct-acting antivirals in the postliver transplant setting is easier, shorter, tolerable, and more effective with high-sustained virological response rates. However, some challenges remain, including the optimal timing of therapy, drug-drug interactions, renal insufficiency, and HIV coinfection. SUMMARY:Patients with recurrent HCV following liver transplant will significantly benefit from all oral new direct acting antivirals. Ongoing studies will determine the optimal timing and combination in this unique population.
Authors: Marc Puigvehí; Dana Hashim; Philipp K Haber; Amreen Dinani; Thomas D Schiano; Amon Asgharpour; Tatyana Kushner; Gaurav Kakked; Parissa Tabrizian; Myron Schwartz; Ahmet Gurakar; Douglas Dieterich; Paolo Boffetta; Scott L Friedman; Josep M Llovet; Behnam Saberi Journal: Am J Transplant Date: 2019-10-11 Impact factor: 8.086